{'fraction_non_alphanumeric': 0.03582089552238806, 'fraction_numerical': 0.019402985074626865, 'mean_word_length': 5.989583333333333, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Ten years of consecutive influenza surveillance to neuraminidase inhibitors resistance Brazil

Introduction: Influenza virus (IV) causes annual epidemics and has the potential for pandemics. IV infections treatment is currently performed with neuraminidase inhibitors (NAIs), mainly oseltamivir (OST). As IVs are constantly evolving, antiviral resistance due to adaptations in influenza genome may occur. Since the 2009 pandemic, NAIs resistant strains frequency has remained low (<2%) worldwide. In Brazil, our group has monitored these strains since 2009 and we have reported A(H1N1)pdm09 strains carrying NA substitutions associated with NAIs reduced inhibition (RI).